Difference between revisions of "Resource:A2c18386-f92b-4d91-83a2-98a0792e7dce"
From The Embassy of Good Science
(Created page with "{{Resource |Resource Type=Guidelines |Title=Guidance on the Management of Clinical Trials during the COVID-19 Pandemic |Is About=Example |Important For=All stakeholders in res...") |
|||
| Line 2: | Line 2: | ||
|Resource Type=Guidelines | |Resource Type=Guidelines | ||
|Title=Guidance on the Management of Clinical Trials during the COVID-19 Pandemic | |Title=Guidance on the Management of Clinical Trials during the COVID-19 Pandemic | ||
| − | |Is About= | + | |Is About= Guidance for all parties involved in clinical trials during the current COVID-19 outbreak. The document aims to provide guidance and prevent the disruption of clinical trials in Europe during the ongoing public health crisis. Even when health systems reach their limits, the integrity of clinical trials, the rights and safety of trial participants and trial staff must be preserved. To maintain so, this guideline provides harmonized and pragmatic measures. |
| + | |||
| + | |Important Because= In the period of a major public health crisis, pragmatic actions are required to ensure the integrity of research. This document provides simplified measures to ensure, integrity, safety, and the rights of those involved in research trials during the ongoing pandemic. | ||
| + | |||
|Important For=All stakeholders in research | |Important For=All stakeholders in research | ||
}} | }} | ||
| Line 9: | Line 12: | ||
}} | }} | ||
{{Related To}} | {{Related To}} | ||
| − | {{Tags}} | + | {{Tags |
| + | |Involves= European Commission; European Medicines Agency (EMA); Heads of Medicines Agencies | ||
| + | |Has Timepoint=2021 | ||
| + | |Has Virtue And Value= Flexibility; Integrity; Safety; | ||
| + | |||
| + | }} | ||
Revision as of 11:08, 7 June 2021
ResourcesGuidelines
Guidance on the Management of Clinical Trials during the COVID-19 Pandemic
What is this about?
Guidance for all parties involved in clinical trials during the current COVID-19 outbreak. The document aims to provide guidance and prevent the disruption of clinical trials in Europe during the ongoing public health crisis. Even when health systems reach their limits, the integrity of clinical trials, the rights and safety of trial participants and trial staff must be preserved. To maintain so, this guideline provides harmonized and pragmatic measures.
Why is this important?
In the period of a major public health crisis, pragmatic actions are required to ensure the integrity of research. This document provides simplified measures to ensure, integrity, safety, and the rights of those involved in research trials during the ongoing pandemic.
